«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2023年04期

页码:

596-600

栏目:

综述

出版日期:

2023-08-20

文章信息/Info

Title:

-

作者:

杜静怡; 徐兴祥

225001 扬州,江苏省苏北人民医院呼吸科

Author(s):

-

关键词:

循环肿瘤细胞;  非小细胞肺癌;  生物标志物;  液体活检

Keywords:

-

分类号:

R563,RR734.2

DOI:

10.3877/cma.j.issn.1674-6902.2023.04.041

摘要:

-

Abstract:

-

参考文献/References:

1 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
2 Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409.
3 Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death.[J]. Aust Med J, 1869, 14(3): 146-149.4 Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(12): 1556-1563.5 Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase Ⅲ trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2014, 32(11): 1136-1142.
6 Hanssen A, Loges S, Pantel K, et al. Detection of circulating tumor cells in non-small cell lung cancer[J]. Front Oncol, 2015, 5: 207.
7 Gabriel MT, Calleja LR, Chalopin A, et al. Circulating tumor cells: A review of non-EpCAM-based approaches for cell enrichment and isolation[J]. Clin Chem, 2016, 62(4): 571-581.
8 De Wit S, Van Dalum G, Lenferink AT, et al. The detection of EpCAM(+)and EpCAM(-)circulating tumor cells[J]. Sci Rep, 2015, 5: 12270.
9 Grover PK, Cummins AG, Price TJ, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research[J]. Ann Oncol, 2014, 25(8): 1506-1516.
10 Zhou N, Wang H, Liu H, et al. MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer[J]. J Exp Clin Cancer Res, 2015, 34: 157.
11 Ilyas A, Asghar W, Kim YT, et al. Parallel recognition of cancer cells using an addressable array of solid-state micropores[J]. Biosens Bioelectron, 2014, 62: 343-349.
12 Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016, 6(5): 479-491.
13 Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research[J]. Nat Rev Cancer, 2014, 14(9): 623-631.
14 Kim TH, Lim M, Park J, et al. FAST: Size-selective, clog-free isolation of rare cancer cells from whole blood at a liquid-liquid interface[J]. Anal Chem, 2017, 89(2): 1155-1162.
15 Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells[J]. EMBO Mol Med, 2015, 7(1): 1-11.
16 Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells[J]. N Engl J Med, 2008, 359(4): 366-377.
17 Gascoyne PR, Noshari J, Anderson TJ, et al. Isolation of rare cells from cell mixtures by dielectrophoresis[J]. Electrophoresis, 2009, 30(8): 1388-1398.
18 De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2008, 14(19): 6302-6309.
19 Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4): 406-414.
20 Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG,AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer[J]. Cancer Res, 2009, 69(7): 2912-2918.
21 Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer[J]. Clin Cancer Res, 2009, 15(22): 6980-6986.
22 Ilie M, Hofman V, Long-Mira E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014, 9(10): e111597.
23 Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011, 17(4): 827-835.
24 Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer[J]. Transl Oncol, 2013, 6(6): 697-702.
25 Wang L, Wu C, Qiao L, et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer[J]. J Cancer, 2017, 8(1): 104-110.
26 Thomas A, Maltzman J, Hassan R. Farletuzumab in lung cancer[J]. Lung Cancer, 2013, 80(1): 15-18.
27 Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay[J]. Anal Biochem, 2005, 338(2): 284-293.
28 Nunez MI, Behrens C, Woods DM, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFRmutation[J]. J Thorac Oncol, 2012, 7(5): 833-840.
29 Bayarri-Lara C, Ortega FG, Cueto Ladrón De Guevara A, et al. Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J]. PLoS One, 2016, 11(2): e0148659.
30 Wang J, Wang K, Xu J, et al. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis[J]. PLoS One, 2013, 8(11): e78070.
31 Hofman V, Ilie M I, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search Assay? and the isolation by size of epithelial tumor cell method[J]. Int J Cancer, 2011, 129(7): 1651-1660.
32 Hanssen A, Wagner J, Gorges TM, et al. Characterization of different CTC subpopulations in non-small cell lung cancer[J]. Sci Rep, 2016, 6: 28010.
33 Hirose T, Murata Y, Oki Y, et al. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer[J]. Oncol Res, 2012, 20(2-3): 131-137.
34 Dorsey JF, Kao GD, Macarthur KM, et al. Tracking viable circulating tumor cells(CTCs)in the peripheral blood of non-small cell lung cancer(NSCLC)patients undergoing definitive radiation therapy: pilot study results[J]. Cancer, 2015, 121(1): 139-149.
35 Horton CE, Kamal M, Leslie M, et al. Circulating tumor cells accurately predicting progressive disease after treatment in a patient with non-small cell lung cancer showing response on scans[J]. Anticancer Res, 2018, 38(2): 1073-1076.
36 Xu YH, Zhou J, Pan XF. Detecting circulating tumor cells in patients with advanced non-small cell lung cancer[J]. Genet Mol Res, 2015, 14(3): 10352-10358.
37 Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
38 Mamdani H, Ahmed S, Armstrong S, et al. Blood-based tumor biomarkers in lung cancer for detection and treatment[J]. Transl Lung Cancer Res, 2017, 6(6): 648-660.
39 Villaflor V, Won B, Nagy R, et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer[J]. Oncotarget, 2016, 7(41): 66880-66891.
40 Santarpia M, Liguori A, D'aveni A, et al. Liquid biopsy for lung cancer early detection[J]. J Thorac Dis, 2018, 10(Suppl 7): S882-s897.
41 Mccoach CE, Blakely CM, Banks KC, et al. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24(12): 2758-2770.
42 Tong B, Xu Y, Zhao J, et al. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer[J]. Thorac Cancer, 2018, 9(5): 640-645.
43 Ilie M, Hofman V, Dietel M, et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients[J]. Virchows Arch, 2016, 468(5): 511-525.
44 Ilié M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer[J]. Ann Oncol, 2018, 29(1): 193-199.
45 Nicolazzo C, Raimondi C, Mancini M, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab[J]. Sci Rep, 2016, 6: 31726.
46 Ligthart ST, Coumans FA, Bidard FC, et al. Circulating tumor cells count and morphological features in breast, colorectal and prostate cancer[J]. PLoS One, 2013, 8(6): e67148.

备注/Memo

备注/Memo:

收稿日期:2023-01-17)
通信作者: 徐兴祥, Email: xuxx63@sina.com

常用功能

更新日期/Last Update: 2023-08-20